The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : Role of chronic hepatitis B virus infection and aflatoxin B1 exposure

Liver International

Volumn 35, Issue 3, 2015, Pages 999-1009

  Qi, Lu Nan ^a   Bai, Tao ^a   Chen, Zu Shun ^a   Wu, Fei Xiang ^a   Chen, Yuan Yuan ^b   De Xiang, Bang ^a   Peng, Tao ^b   Han, Ze Guang ^c   Li, Le Qun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^c CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Aflatoxin B1; Guangxi area; Hepatitis B virus; Hepatocellular carcinoma; P53 mutation

Indexed keywords

AFLATOXIN B1; PROTEIN P53;

ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CHINA; CONTROLLED STUDY; EXON; GENE; GENE MUTATION; GENETIC ASSOCIATION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; NONHUMAN; P53 GENE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; ADULT; CARCINOGENESIS; CASE CONTROL STUDY; COMPLICATION; DRUG EFFECTS; FEMALE; GENETICS; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; PROSPECTIVE STUDY; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; VIROLOGY;

ADULT; AFLATOXIN B1; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENES, P53; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922698270     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12460     Document Type: Article

References (50)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003; 21: 271-6.
3. Blons H, Laurent-Puig P. TP53 and head and neck neoplasms. Hum Mutat 2003; 21: 252-7.
4. Huy TT, Abe K. Molecular epidemiology of hepatitis B and C virus infections in Asia. Pediatr Int 2004; 46: 223-30.
5. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-85.
6. London WT, Evans AA, Buetow K, et al. Molecular and genetic epidemiology of hepatocellular carcinoma: studies in China and Senegal. Princess Takamatsu Symp 1995; 25: 51-60.
7. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S294-308.
8. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010; 118: 818-24.
9. Hamid AS, Tesfamariam IG, Zhang Y, Zhang ZG. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol Lett 2013; 5: 1087-92.
10. Liu ZM, Li LQ, Peng MH, et al. Hepatitis B virus infection contributes to oxidative stress in a population exposed to aflatoxin B1 and high-risk for hepatocellular carcinoma. Cancer Lett 2008; 263: 212-22.
11. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 2001; 22: 535-45.
12. Groopman JD, Kensler TW. Role of metabolism and viruses in aflatoxin-induced liver cancer. Toxicol Appl Pharmacol 2005; 206: 131-7.
13. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003; 23: 405-9.
14. Yeh FS, Yu MC, Mo CC, et al. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 1989; 49: 2506-9.
15. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
16. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat 2003; 21: 285-91.
17. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat 2003; 21: 201-16.
18. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 1993; 90: 8586-90.
19. Pineau P, Marchio A, Battiston C, et al. Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res 2008; 653: 6-13.
20. Gouas D, Shi H, Hainaut P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett 2009; 286: 29-37.
21. Besaratinia A, Kim S I, Hainaut P, Pfeifer G P. In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology 2009; 137: 1127-37, 37 e1-5.
22. Kress S, Jahn UR, Buchmann A, Bannasch P, Schwarz M. p53 Mutations in human hepatocellular carcinomas from Germany. Cancer Res 1992; 52: 3220-3.
23. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992; 52: 6358-64.
24. Ozdemir FT, Tiftikci A, Sancak S, et al. The prevalence of the mutation in codon 249 of the P53 gene in patients with hepatocellular carcinoma (HCC) in Turkey. J Gastrointest Cancer 2010; 41: 185-9.
25. Shirabe K, Toshima T, Taketomi A, et al. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan. Liver Int 2011; 31: 1366-72.
26. Ortiz-Cuaran S, Villar S, Gouas D, et al. Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand. Cancer Lett 2013; 331: 46-51.
27. Lereau M, Gouas D, Villar S, et al. Interactions between hepatitis B virus and aflatoxin B(1): effects on p53 induction in HepaRG cells. J Gen Virol 2012; 93(Pt 3): 640-50.
28. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48(Suppl 1): S20-37.
29. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
30. Katiyar S, Dash BC, Thakur V, et al. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 2000; 88: 1565-73.
31. Stern MC, Umbach DM, Yu MC, et al. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001; 10: 617-25.
32. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-58.
33. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-13.
34. Jia L, Wang XW, Harris CC. Hepatitis B virus X protein inhibits nucleotide excision repair. Int J Cancer 1999; 80: 875-9.
35. Lian Z, Liu J, Pan J, et al. A cellular gene up-regulated by hepatitis B virus-encoded X antigen promotes hepatocellular growth and survival. Hepatology 2001; 34: 146-57.
36. Scorsone KA, Zhou YZ, Butel JS, Slagle BL. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 1992; 52: 1635-8.
37. Lunn RM, Zhang YJ, Wang LY, et al. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997; 57: 3471-7.
38. Bedard LL, Massey TE. Aflatoxin B1-induced DNA damage and its repair. Cancer Lett 2006; 241: 174-83.
39. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-63.
40. Laval F, Wink DA, Laval J. A discussion of mechanisms of NO genotoxicity: implication of inhibition of DNA repair proteins. Rev Physiol Biochem Pharmacol 1997; 131: 175-91.
41. Shimoda R, Nagashima M, Sakamoto M, et al. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res 1994; 54: 3171-2.
42. Mannick JB, Hausladen A, Liu L, et al. Fas-induced caspase denitrosylation. Science 1999; 284: 651-4.
43. Wang XW, Gibson MK, Vermeulen W, et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995; 55: 6012-6.
44. Elmore LW, Hancock AR, Chang SF, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A 1997; 94: 14707-12.
45. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-9.
46. Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, et al. Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PLoS ONE 2012; 7: e37707.
47. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes & cancer 2011; 2: 466-74.
48. Saxena A, Shukla SK, Prasad KN, Ghoshal UC. Analysis of p53, K-ras gene mutation & Helicobacter pylori infection in patients with gastric cancer & peptic ulcer disease at a tertiary care hospital in north India. Indian J Med Res 2012; 136: 664-70.
49. Gouas DA, Shi H, Hautefeuille AH, et al. Effects of the TP53 p. R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis 2010; 31: 1475-82.
50. Qin G, Su J, Ning Y, et al. p53 protein expression in patients with hepatocellular carcinoma from the high incidence area of Guangxi, Southern China. Cancer Lett 1997; 121: 203-10.